// App-Quantinova.ai

e14125 : Population pharmacokinetics (pop PK) and exposure-safety analysis to reveal patient factors that affect AMG 900 tolerability.

Researchers

Presenter

  • Vincent F-S. Chow

Principal Investigators

  • Joanna Z. Peng

  • Florian D. Vogl

  • John P. Gibbs

Medical Centers

  • Amgen Inc, Thousand Oaks, CA

  • Seattle Genetics, Bothell, WA

Locations

  • United States

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Solid malignancies

  • Neutropenia

Biomarkers

  • Cytochrome P450 Family 3 Subfamily A Member 4

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • AMG-900

  • Filgrastim

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT00858377

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved